161 results
Page 3 of 9
8-K
5dy2s1hns583
15 Mar 21
Other Events
5:11pm
8-K
EX-99.1
y6qtmv xy
25 Feb 21
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
7:17am
DEFM14A
zonv965p05w43es
11 Feb 21
Proxy related to merger
4:19pm
PREM14A
01lpyki
29 Jan 21
Preliminary proxy related to merger
4:22pm
8-K
EX-99.1
apwadtw2og 7g
29 Jan 21
Index to Consolidated Financial Statements
4:08pm
8-K
EX-99.1
d2n9 wwtbsy0b9a4
26 Jan 21
Other Events
4:14pm
DEFA14A
v8p2x
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
pyzmolsolom1gz6 bzx0
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.1
jaf3htoc6 ac4fvkkkr3
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
DEFA14A
i1928k c0y9
23 Dec 20
Additional proxy soliciting materials
4:52pm
DEFA14A
uobw40wxl q6vzwjce5a
21 Dec 20
Additional proxy soliciting materials
9:17pm
DEFA14A
EX-2.1
86vvssefxinq
21 Dec 20
Additional proxy soliciting materials
9:17pm
8-K
EX-2.1
o0x6ll g0l
21 Dec 20
Entry into a Material Definitive Agreement
9:15pm
8-K
8qw zibpiqehbme06e
21 Dec 20
Entry into a Material Definitive Agreement
9:15pm
DEFA14A
EX-99.1
rtr1mn9vzkosthp2
21 Dec 20
Additional proxy soliciting materials
7:10am
DEFA14A
EX-99.2
z7v7s04vg4e1m
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
w9rglt526bc 75
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.2
1obpju
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
lng37d dnc4
7 Dec 20
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
4:53pm